Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens

Vaccine. 2001 Jun 14;19(27):3652-60. doi: 10.1016/s0264-410x(01)00086-x.

Abstract

Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical intraepithelial neoplasia (CIN) and cancer. A newly designed vaccine, comprising the HPV16 L2, E6 and E7 as a single fusion protein (TA-CIN), was shown to elicit HPV16-specific CTL, T-helper cells and antibodies in a pre-clinical mouse model. These immune responses effectively prevented outgrowth of HPV16-positive tumour cells in a prophylactic setting as well as in a minimal residual disease setting. CTL immunity was optimally induced when TA-CIN was employed in heterologous prime-boost regimens in combination with TA-HPV, a clinical grade vaccinia-based vaccine. These data provide a scientific basis for the use of TA-CIN, alone or in combination with TA-HPV in future human trials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Neoplasm / administration & dosage
  • Antigens, Neoplasm / immunology
  • Antigens, Neoplasm / therapeutic use
  • Antigens, Neoplasm / toxicity
  • Antigens, Viral / administration & dosage
  • Antigens, Viral / immunology
  • Antigens, Viral / therapeutic use
  • Antigens, Viral / toxicity
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use
  • Cancer Vaccines / toxicity*
  • Capsid / administration & dosage
  • Capsid / immunology
  • Capsid / therapeutic use
  • Capsid / toxicity*
  • Capsid Proteins*
  • Cell Line
  • Cell Line, Transformed
  • Cervical Intraepithelial Neoplasia / prevention & control
  • Cervical Intraepithelial Neoplasia / therapy
  • Cervical Intraepithelial Neoplasia / virology
  • Drug Evaluation, Preclinical
  • Immunotherapy
  • Mice
  • Mice, Inbred C57BL
  • Oncogene Proteins, Viral / administration & dosage
  • Oncogene Proteins, Viral / immunology
  • Oncogene Proteins, Viral / therapeutic use
  • Oncogene Proteins, Viral / toxicity*
  • Papillomaviridae / immunology*
  • Papillomavirus E7 Proteins
  • Recombinant Fusion Proteins / administration & dosage
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / therapeutic use
  • Recombinant Fusion Proteins / toxicity*
  • Vaccines, Acellular / administration & dosage
  • Vaccines, Acellular / immunology
  • Vaccines, Acellular / therapeutic use
  • Vaccines, Acellular / toxicity

Substances

  • Antigens, Neoplasm
  • Antigens, Viral
  • Cancer Vaccines
  • Capsid Proteins
  • L2 protein, Human papillomavirus type 16
  • Oncogene Proteins, Viral
  • Papillomavirus E7 Proteins
  • Recombinant Fusion Proteins
  • Vaccines, Acellular
  • oncogene protein E7, Human papillomavirus type 16